PHVS

Pharvaris NV

Add to Watchlist

Advanced Chart

16.560

+0.650(+4.090%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

16.610

Open

15.500

VWAP

16.15

Vol

40.38K

Mkt Cap

902.41M

Low

15.500

Amount

652.32K

EV/EBITDA(TTM)

Total Shares

53.82M

647.39M

EV/OCF(TTM)

P/S(TTM)

Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

-0.784

+42.55%

-0.838

+8.83%

-0.827

+29.25%

Estimates Revision

Stock Price

Go Down

-2.47%

In Past 3 Month

6 Analyst Rating

103.32% Upside

Wall Street analysts forecast PHVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHVS is 33.67 USD with a low forecast of 14.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

1 Sell

Moderate Buy

103.32% Upside

Current: 16.560

Low

14.00

Averages

33.67

High

55.00

103.32% Upside

Current: 16.560

Low

14.00

Averages

33.67

High

55.00

Cantor Fitzgerald

Timur Ivannikov

Buy

Maintains

$28 → $25

2025-05-14

New

Reason

Cantor Fitzgerald

Timur Ivannikov

Price Target

$28 → $25

2025-05-14

New

Maintains

Buy

Reason

Cantor Fitzgerald

Steven Seedhouse

Buy

Initiates

$28

2025-04-29

Reason

Cantor Fitzgerald

Steven Seedhouse

Price Target

$28

2025-04-29

Initiates

Buy

Reason

Cantor Fitzgerald initiated coverage of Pharvaris with an Overweight rating and $28 price target.

Citizens Capital Markets

Jonathan Wolleben

Buy

Reiterates

$55

2025-03-03

Reason

Citizens Capital Markets

Jonathan Wolleben

Price Target

$55

2025-03-03

Reiterates

Buy

Reason

JMP Securities

Jonathan Wolleben

Buy

Maintains

$46 → $55

2025-01-31

Reason

JMP Securities

Jonathan Wolleben

Price Target

$46 → $55

2025-01-31

Maintains

Buy

Reason

JMP Securities analyst Jonathan Wolleben raised the firm's price target on Pharvaris to $55 from $46 and keeps an Outperform rating on the shares. Pharvaris is the only company with an oral candidate for hereditary angioedema prophylaxis and on demand treatment, the analyst tells investors. Additionally, the company's extended release version of deucrictibant will be poised to be take prophylactic market share if its Phase 3 replicates the impressive Phase 2 data, JMP says.

Jones Trading

Debanjana Chatterjee

Strong Buy

Initiates

$46

2024-09-19

Reason

Jones Trading

Debanjana Chatterjee

Price Target

$46

2024-09-19

Initiates

Strong Buy

Reason

JonesResearch initiated coverage of Pharvaris with a Buy rating and $46 price target. The company's oral deucrictibant has promising efficacy and safety in hereditary angioedema, both as an on-demand therapy for acute attacks and in long-term prophylactic settings, the analyst tells investors in a research note. The firm says deucrictibant's differentiated profile could drive blockbuster sales.

Oppenheimer

Justin Kim

Buy

Maintains

$38 → $42

2024-09-06

Reason

Oppenheimer

Justin Kim

Price Target

$38 → $42

2024-09-06

Maintains

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Pharvaris NV (PHVS.O) is -4.55, compared to its 5-year average forward P/E of -6.89. For a more detailed relative valuation and DCF analysis to assess Pharvaris NV 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.89

Current PE

-4.55

Overvalued PE

-4.25

Undervalued PE

-9.54

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.36

Current EV/EBITDA

-3.48

Overvalued EV/EBITDA

-1.38

Undervalued EV/EBITDA

-7.34

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00